In our study, both the absolute number of HER2amp CTC and the HER2amp/HER2-negative CTC ratio were low, suggesting that these HER2amp CTC account for a minority of the tumor burden and that HER2amp subclones do not expand significantly during therapy in MBC patients. This evidence concerns the gene ERBB2 and neoplasm.